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in other locations around the world, and intrigued by multiple
possibilities to further expand it. n
Author disclosures are available with the text of this letter at
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Improving Lung Cancer Screening Uptake
To the Editor:
The recent article by Quaife and colleagues (1) and the accompanying
editorial by Burnett-Hartman and Wiener (2) report the results of the
LSUT (Lung Screen Uptake Trial) from London and provide comments
from Boston. The trial is important because it provides evidence that
there may be ways to improve the dismal uptake of lung cancer
screening, especially in higher-risk, underserved populations. The
editorialists point out some differences between the United Kingdom
and United States, including the important fact that patient contact
came from the individual primary care physician, which is in contrast to
the approach used in the United States, where many patients do not
have an identifiable primary care physician. There are other important
factors, including the emphasis on the “Lung Health Check” rather than
on more narrow lung cancer screening and the absence of copays
or other financial disincentives for computed tomographic scans in
the United Kingdom compared with the United States. In PLuSS
(Pittsburgh Lung Screening Study) (3), we have also emphasized total
lung health by providing annual spirometry, and we have eliminated
financial barriers by waving all copays. We have also been using
the electronic health record to identify potential candidates for lung
screening. As our ability to obtain more information from the low-dose
computed tomographic scans by radiomic advances, we hopefully can
rebrand lung cancer screening in the United States, maybe as heart and
lung screening, to facilitate more widespread use. n
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Reply to Wilson
From the Authors:
We read Wilson’s response letter to both our LSUT (Lung Screen Uptake
Trial) (1) and the accompanying editorial by Burnett-Hartman and
Wiener (2) with great interest and value the insightful discussion they
raise. Together we share in the challenge of achieving both equitable and
informed uptake of low-dose computed tomography lung cancer screening
by high-risk individuals, but the differences between the United Kingdom
and United States that Wilson raises are important for how we intervene.
The United Kingdom benefits from a coordinated and universal primary
care system, and we appreciate that sending postal invitations directly from
the individual’s primary care physician is a strategy that may not translate
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directly to the U.S. context. We also note the requirement by the Centers
for Medicare and Medicaid for a separate shared decision-making session
before the screening intervention in the United States. However, evidence
suggests that the behavioral components of LSUT’s strategy (healthcare
professional endorsement and proactively inviting and arranging
appointments) are the “active ingredients” that could be implemented in
different ways in the U.S. context.
We also share Wilson’s interest in broadening LSUT’s “Lung Health
Check” approach to screening to include other aspects of lung and heart
health in the future. Framing lung cancer screening as one optional test
within a “Lung Health Check” was intended to improve engagement
by minimizing fear (that could lead to information avoidance and
uninformed nonparticipation) and to provide an in-person supportive
environment where shared decision-making about the screening offer
could be achieved. Through this we found potential for other lung and
heart health interventions—the key focus of Wilson and colleagues’ point.
This includes parallels with the PLuSS (Pittsburgh Lung Cancer Screening
Study) (3), which found that the prevalence of emphysema and airway
obstruction increased with individual lung cancer risk. For
example, work led by Ruparel and colleagues (4) found a
significant proportion of undiagnosed chronic obstructive
pulmonary disease and untreated coronary artery calcification (5)
within our LSUT cohort, suggesting opportunities for early
diagnosis of chronic obstructive pulmonary disease, instigating
cardiovascular risk assessment and primary prevention. The UK
taxpayer’s universal healthcare system may in the future fund
low-dose computed tomography screening scans, and so we
would not have the financial disincentives that the United States
has in this respect. However, the United Kingdom does have
limited resources for subsequent healthcare provision for
incidental findings. This makes the feasibility of delivering a
holistic health assessment challenging and policy decision-makers
would (rightly) first require evidence for the public health benefit
and cost-effectiveness of such an approach. n
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Airway Disease Presenting as Restrictive Impairment
To the Editor:
Eddy and coworkers (1) have earned the appreciation of pulmonary
clinicians and physiologists for providing both a physiologic and an
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